Clinical Trials Logo

Benign Prostatic Hyperplasia (BPH) clinical trials

View clinical trials related to Benign Prostatic Hyperplasia (BPH).

Filter by:

NCT ID: NCT02855892 Completed - Clinical trials for Benign Prostatic Hyperplasia (BPH)

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This clinical trial is designed as a randomized, placebo-controlled, single-blind, parallel design, multi-center, phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia. Eligible subjects are randomized into a group out of the three study groups and a placebo group after four weeks of placebo run-in period. Placebo run-in period is concurrently proceeded as a wash-out period for previous treatment of benign prostatic hyperplasia, and a placebo is administered intradermally twice with two-week interval during this period. After that, the randomized subjects receive a study drug and a placebo intradermally seven times with two-week interval by visiting at Week 0, 2, 4, 6, 8, 10, and 12. After the treatment period, the subjects additionally visit at Week 13 and 16, and the efficacy is evaluated at Week 4, 8, 12, 13, and 16, and the safety is evaluated over the 16-week period.

NCT ID: NCT02625545 Recruiting - Clinical trials for Benign Prostatic Hyperplasia (BPH)

Study of Median Lobe Prostatic UroLift Procedure

MedLift
Start date: February 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of using UroLift in subjects with a prostatic median lobe enlargement due to BPH.

NCT ID: NCT02592473 Recruiting - Clinical trials for Prostatic Hyperplasia

Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia

Start date: November 2015
Phase: Phase 1
Study type: Interventional

The purpose of this project is to evaluate the safety, efficacy, and feasibility of performing prostatic artery embolization (PAE) using endovascular techniques and particle embolics in men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).

NCT ID: NCT02505919 Recruiting - Clinical trials for Benign Prostatic Hyperplasia (BPH)

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)

WATER
Start date: September 2015
Phase: Phase 3
Study type: Interventional

A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS). The primary endpoints for safety and effectiveness will be measured at 3 and 6 months, respectively, and subjects will be followed out to 3 years to collect long-term clinical data.

NCT ID: NCT02304549 Completed - Clinical trials for Benign Prostatic Hyperplasia (BPH)

A Prospective Investigation Using the Expired Breath Ethanol Test

Start date: April 2014
Phase: N/A
Study type: Observational

Benign prostatic hyperplasia (BPH) is a prevalent entity, affecting over 50% of men older than 60 years.In cases with moderate to severe lower urinary tract symptoms (LUTS) monopolar transurethral resection of the prostate (TUR-P) is the standard treatment. Especially in frail patients, conventional TUR-P is associated with relevant and potentially deleterious complications, e.g. TUR syndrome. Using isotonic saline, like in bipolar TUR-P and transurethral laser vaporization (TUV-P), TUR syndrome can be prevented. The short-term complication rate with the Thulium laser is similar to the rate described after vaporisation with other laser systems18-23 and less than that with TUR-P. Despite recent publications on the safety and complications with Thulium vaporisation of the prostate, to the investigators knowledge, until now, no prospective trial has directly assessed, whether absorption of irrigation fluid occurs and to what extent in Thulium Laser vaporisation of the prostate. The investigators therefore aim to investigate if absorption of irrigation fluid occurs during Thulium Laser vaporisation of the prostate by expired breath ethanol test.

NCT ID: NCT02121613 Completed - Clinical trials for Benign Prostatic Hyperplasia (BPH)

PERmixon® in LUTS Evaluation Study (PERLES)

PERLES
Start date: April 2014
Phase: Phase 4
Study type: Interventional

The aim of this study is to support the efficacy of Permixon 160 mg b.i.d. in treating subjects with symptomatic Benign Prostatic Hyperplasia (BPH), compared to placebo, using Tamsulosine LP 0.4 mg as a reference treatment.

NCT ID: NCT02026908 Recruiting - Clinical trials for Benign Prostatic Hyperplasia (BPH)

Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)

Start date: January 2014
Phase: N/A
Study type: Interventional

This is an open-labeled, non-randomized feasibility study to evaluate the safety of prostate artery embolization (PAE) for the treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH).

NCT ID: NCT01896973 Recruiting - Clinical trials for Benign Prostatic Hyperplasia (BPH)

Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)

Start date: July 2013
Phase: N/A
Study type: Interventional

The HistoSonics' Histotripsy BPH Device, the Vortx Rx, is a portable ultrasound therapy device. The purpose of this study is to assess and monitor the performance of the Vortx Rx for initial safety and efficacy for the treatment of Benign Prostatic Hyperplasia.

NCT ID: NCT01829893 Completed - Clinical trials for Benign Prostatic Hyperplasia (BPH)

PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination

Start date: January 2012
Phase: Phase 1
Study type: Interventional

To compare the relative bioavailability and pharmacokinetic characteristics of a newly single pill combination of finasteride and tamsulosin with a conventional combination of finasteride and tamsulosin in healthy subjects with a single dose, randomized, open-label, 2-sequence -2period crossover study.

NCT ID: NCT01775488 Withdrawn - Clinical trials for Benign Prostatic Hyperplasia (BPH)

Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada)

Start date: June 2013
Phase: N/A
Study type: Interventional

The HistoSonics' Histotripsy BPH Device, the Vortx Rx, is a portable ultrasound therapy device. The purpose of this study is to assess and monitor the performance of the Vortx Rx for initial safety and efficacy for the treatment of Benign Prostatic Hyperplasia.